The Effects of Vitamin K1 and Warfarin on Prothrombin Expression in Human Hepatoblastoma (HepG2) Cells

C Scott Jamison; Bryan F Burkey; Sandra J Friezner Degen

doi:10.1055/s-0038-1656315

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1992; 68(01): 040-047
DOI: 10.1055/s-0038-1656315

Original Article

Schattauer GmbH Stuttgart

The Effects of Vitamin K₁ and Warfarin on Prothrombin Expression in Human Hepatoblastoma (HepG2) Cells

C Scott Jamison

The Children’s Hospital Research Foundation and the Developmental Biology Graduate Program, University of Cincinnati Medical Center, Cincinnati, Ohio, USA

,

Bryan F Burkey

The Children’s Hospital Research Foundation and the Developmental Biology Graduate Program, University of Cincinnati Medical Center, Cincinnati, Ohio, USA

,

Sandra J Friezner Degen

The Children’s Hospital Research Foundation and the Developmental Biology Graduate Program, University of Cincinnati Medical Center, Cincinnati, Ohio, USA

› Author Affiliations

Abstract

PDF Download

Summary

Cultures of human hepatoblastoma (HepG2) cells were treated with vitamin K₁ or warfarin and prothrombin antigen and mRNA levels were determined. With 3 and 6 h of 10 µg vitamin K₁ treatment secreted prothrombin antigen levels, relative to total secreted protein levels, were increased 1.5-fold and 2.1-fold, respectively, over ethanol-treated control levels as determined by an enzyme-linked immunosorbent assay. Dose-response analysis with 3 h of 25 µg/ml vitamin K₁ treatment demonstrated a maximal increase of 2.0-fold in secreted prothrombin antigen levels, relative to total secreted protein levels, over ethanol-treated control levels. Pulse-chase analysis with ³⁵S-methionine and immunoprecipitation of ³⁵S-labelled prothrombin demonstrated that, with vitamin K₁ treatment (25 µg/ml, 3 h), the rate of prothrombin secretion increased approximately 2-fold and the total amount (intra- and extracellular) of prothrombin synthesized increased approximately 50% over ethanol-treated control levels. Warfarin treatment (1, 5, or 10 µg/ml, 24 h) resulted in decreases in secreted prothrombin antigen levels, relative to total protein levels to approximately 85%, 87% or 81% of ethanol-treated control levels. Analysis of total RNA isolated from these cultures by Northern and solution hybridization techniques demonstrated that prothrombin mRNA was approximately 2.1 kb and that neither vitamin K₁ nor warfarin treatment affected the quantity of prothrombin mRNA (ranging from 240–350 prothrombin mRNA molecules per cell). These results demonstrate that vitamin K₁ and warfarin, in addition to effects on γ-carboxylation, affect prothrombin synthesis post-transcriptionally, perhaps influencing translation, post-translational processing and/or secretion mechanisms.

PDF (1146 kb)

References

References
1 Davie EW, Fujikawa K. Basic mechanisms in blood coagulation. Annu Rev Biochem 1975; 44: 799-829
2 Davie EW, Fujikawa K, Kurachi K, Kisiel W. The role of serine proteases in the blood coagulation cascade. Adv Enzymol 1979; 48: 277-318
3 Jackson CM, Nemerson Y. Blood coagulation. Annu Rev Biochem 1980; 49: 765-811
4 Kisiel W, Hanahan DJ. Purification and characterization of human factor II. Biochim Biophys Acta 1973; 304: 103-113
5 Barnhart MI. Cellular site for prothrombin synthesis. Am J Physiol 1960; 199: 360-366
6 Walz DA, Hewett-Emmett D, Guillin M-C. Amino acid sequences and molecular homology of the vitamin K-dependent clotting factors. Prothrombin and Other Vitamin K Proteins, vol 1. CRC Press, Inc.; Boca Raton, FL: 1986: 125-160
7 Stenflo J, Fernlund P, Egan W, Roepstorff P. Vitamin K Dependent Modifications of Glutamic Acid Residues in Prothrombin. Proc Natl Acad Sci, USA 1974; 71: 2730-2733
8 Nelsestuen GL, Zytkovicz TH, Howard JB. The mode of action of vitamin K: identification of γ-carboxyglutamic acid as a component of prothrombin. J Biol Chem 1974; 249: 6347-6350
9 Stenflo J, Suttie JW. Vitamin K-dependent formation of γ-carboxyglutamic acid. Annu Rev Biochem 1977; 46: 157-172
10 Suttie JW. Vitamin K-dependent carboxylase. Annu Rev Biochem 1985; 54: 459-477
11 Suttie JW. Vitamin K-dependent carboxylation of glutamyl residues in proteins. Biofactors 1988; 1: 55-60
12 Esmon CT, Sadowski JA, Suttie JW. A new carboxylation reaction: the vitamin K-dependent incorporation of H¹⁴CO₃ ^– into prothrombin. J Biol Chem 1975; 250: 4744-4748
13 Munns TW, Johnston MFM, Liszewski MK, Olson RE. Vitamin K-dependent synthesis and modification of precursor prothrombin in cultured H-35 hepatoma cells. Proc Natl Acad Sci USA 1976; 73: 2803-2807
14 Fair DS, Bahnak BR. Human hepatoma cells secrete single chain factor X, prothrombin, and antithrombin III. Blood 1984; 64: 194-204
15 Karpatkin S, Finlay TH, Ballesteros AL, Karkpatkin M. Effect of warfarin on prothrombin synthesis and secretion in human HEP G2 cells. Blood 1987; 70: 773-778
16 Knowles BB, Howe CC, Aden DP. Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science 1980; 209: 497-499
17 Javitt NB. Hep G2 cells as a resource for metabolic studies: lipoprotein, cholesterol, and bile acids. FASEB J 1990; 4: 161-168
18 Fair DS, Marlar RA. Biosynthesis and secretion of factor VII, protein C, protein S, and the protein C inhibitor from a human hepatoma cell line. Blood 1986; 67: 64-70
19 Glisin V, Crkvenjakov R, Byus C. Ribonucleic acid isolated by cesium chloride centrifugation. Biochemistry 1974; 13: 2633-2637
20 Selden RF. Analysis of RNA by Northern Hybridization. In: Current Protocols in Molecular Biology. John Wiley and Sons; New York, NY: 1989: 4.9.1-.8
21 Jamison CS, Degen SJF. Prenatal and postnatal expression of mRNA coding for rat prothrombin. Biochim Biophys Acta 1991; 1088: 208-216
22 Degen SJF, MacGillivray RTA, Davie EW. Characterization of the complementary deoxyribonucleic acid and gene coding for human prothrombin. Biochemistry 1983; 22: 2087-2097
23 Feinberg AP, Vogelstein B. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem 1983; 132: 6-13
24 Feinberg AP, Vogelstein B. ADDENDUM: A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem 1984; 137: 266-267
25 Durnam DM, Palmiter RD. A practical approach for quantitating specific mRNAs by solution hybridization. Anal Biochem 1983; 131: 385-393
26 de Silva HV, Stuart WD, Park YB, Mao SJT, Gil CM, Wetterau JR, Busch SJ, Harmony JAK. Purification and characterization of apolipoprotein J. J Biol Chem 1990; 265: 14292-14297
27 Burkey BF, de Silva HV, Harmony JAK. The intracellular processing of apolipoprotein J precursor to the mature heterodimer. J Lipid Res 1991; 32: 1039-1048
28 Olson RE. Vitamin K. Hemostasis and Thrombosis, Basic Principles and Clinical Practice, 2nd ed. JB Lippincott Company; Philadelphia, PA: 1987: 846-860
29 Lane PA, Hathaway WE. Vitamin K in infancy. J Pediatr 1985; 106: 351-359
30 Jamison CS, Degen SWF. Non-specific effects of aquaMEPHYTON (vitamin K₁) on prothrombin expression in human hepatoblastoma (HepG2) cells. Thromb Res 1992; 65: 409-419
31 Morrissey JJ, Jones JP, Olson RE. Isolation and characterization of isoprothrombin in the rat. Biochem Biophys Res Comm 1973; 54: 1075-1082
32 Suttie JW. Mechanism of action of vitamin K: demonstration of a liver precursor of prothrombin. Science 1973; 179: 192-194
33 Shah DV, Suttie JW, Grant GA. A rat liver protein with potential thrombin activity: properties and partial purification. Arch Biochem Biophys 1973; 159: 483-491